A Financial Comparison between Biogen and Corixa
$1.95
2 word format
document in english
finance
market study
date published 12/09/2007
review : not yet assessed
level : General public
requested 6 times
SummaryBased on the ratios in Appendix A, it seems that Biogen does not have a high profitability. The values of the ROE, ROA, and Earnings per Share ratios are all negative, and the Profit Margin ratio is only 1.2884%; however, when compared to its competitor, Corixa Corporation, these numbers dominate. It is a trend of the industry to produce low ratios. Biogen has a wider variety of products than its competitor, Corixa. Most of the medications that they have are being tested and are not yet for sale, as with Corixa, but Biogen clearly has a wider variety of products on the market. This is quite an advantage considering that it takes a long time for new drugs to enter the market. The cash flows from operating activities amounts to $267,077 while the net income was only $199,148. The difference between these two numbers is $67,929. This indicates that Biogen is gaining a substantial amount of money from other operating activities besides those that lead to an increase in net income. This indicates that they operate efficiently.
Table of Contents
- Biogen is capable of meeting its current obligations as they become due.
- A proxy statement is a document which the SEC requires a company to send to its shareholders that provides material facts concerning matters on which the shareholders will vote
- The Finance and Audit Committee acts on behalf of the Board of Directors to oversee all aspects of financial reporting, internal control and audit functions
- This company seems like a safe investment opportunity
- If they have any breakthroughs in developing new products, however, it could launch the price of their stock up a good amount
Most downloaded documents over 30 days in finance Latest in the category finance From the same author
knowledge network